Irisin Levels May Be Metabolic Biomarker for GH Replacement Therapy
Growth hormone replacement can raise irisin levels in children with growth hormone deficiency.
Growth Hormone Deficiency
Normal Height Velocity Maintained With Reduced Growth Hormone Dose
Normal height velocity can be maintained in prepubertal children during the catch-up growth period by reducing growth hormone dosage by 50%.
Safety and Mortality Outcomes Following Pediatric Growth Hormone Therapy
Primary cancer rates and mortality risk were no higher for pediatric patients treated with growth hormone therapy.
Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency
Investigators examined the reliability of the clonidine test in children with short stature who had been evaluated for suspected growth hormone deficiency.
Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
The risk for meningioma was not significantly higher in patients who did not receive radiotherapy.
Grote Clinical Decision Rule May Be Best for Monitoring Growth in Children
Investigators sought to improve growth-monitoring programs by examining existing algorithms and examined the effect of using WHO vs national growth charts on algorithm performance.
Updated Consensus on Management of Acromegaly Includes New Recommendations
Experts in the management of acromegaly provide new recommendations on the medical management of acromegaly since the last published update in 2014.
Pasireotide Improves IGF-1 in Patients Resistant to Somatostatin Analogs
Monthly pasireotide injections may benefit patients with acromegaly who are resistant to first-generation somatostatin analogs.
Accuracy of Diagnostic Tests for GH Deficiency in Childhood Cancer Survivors
The utility of IGF-I and IGFBP-3 for growth hormone testing in childhood cancer survivors was examined.
Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
The Endocrine Society, European Society of Endocrinology, and Pediatric Endocrine Society issue guidelines for the management of hypothalamic-pituitary and growth disorders in childhood cancer survivors.
